WO2004073631A3 - Combination therapy for the treatment of neoplasms - Google Patents

Combination therapy for the treatment of neoplasms Download PDF

Info

Publication number
WO2004073631A3
WO2004073631A3 PCT/US2004/004551 US2004004551W WO2004073631A3 WO 2004073631 A3 WO2004073631 A3 WO 2004073631A3 US 2004004551 W US2004004551 W US 2004004551W WO 2004073631 A3 WO2004073631 A3 WO 2004073631A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neoplasms
combination therapy
kits
cancer
Prior art date
Application number
PCT/US2004/004551
Other languages
French (fr)
Other versions
WO2004073631A2 (en
Inventor
Margaret Lee
Yanzhen Zhang
Curtis Keith
Amy Beth Wilson
Benjamin A Auspitz
James M Nichols
Original Assignee
Combinatorx Inc
Margaret Lee
Yanzhen Zhang
Curtis Keith
Amy Beth Wilson
Benjamin A Auspitz
James M Nichols
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc, Margaret Lee, Yanzhen Zhang, Curtis Keith, Amy Beth Wilson, Benjamin A Auspitz, James M Nichols filed Critical Combinatorx Inc
Publication of WO2004073631A2 publication Critical patent/WO2004073631A2/en
Publication of WO2004073631A3 publication Critical patent/WO2004073631A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention features methods, kits, and compositions for the treatment of cancer and other proliferative diseases.
PCT/US2004/004551 2003-02-14 2004-02-12 Combination therapy for the treatment of neoplasms WO2004073631A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44766303P 2003-02-14 2003-02-14
US60/447,663 2003-02-14

Publications (2)

Publication Number Publication Date
WO2004073631A2 WO2004073631A2 (en) 2004-09-02
WO2004073631A3 true WO2004073631A3 (en) 2007-11-15

Family

ID=32908477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004551 WO2004073631A2 (en) 2003-02-14 2004-02-12 Combination therapy for the treatment of neoplasms

Country Status (1)

Country Link
WO (1) WO2004073631A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383512B1 (en) * 1997-04-30 2002-05-07 American Home Products Corporation Vesicular complexes and methods of making and using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6383512B1 (en) * 1997-04-30 2002-05-07 American Home Products Corporation Vesicular complexes and methods of making and using the same

Also Published As

Publication number Publication date
WO2004073631A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2005030144A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2003082208A3 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2004113275A3 (en) Methods and compositions for treating amyloid-related diseases
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
TW200600087A (en) Methods and compositions for treating amyloid-related diseases
WO2006119329A3 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2006083971A3 (en) Dr5 antibodies and uses thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
WO2006089087A9 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2001079164A3 (en) N-substituted dithiocarbamates for the treatment of biological disorders
WO2004009609A3 (en) Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2006015191A3 (en) Multicyclic lonidamine analogs
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase